EPRX revenueFY2025$0
EPRX revenue was $0 for fiscal 2025 (ended Dec 31, 2025), compared with $0 in fiscal 2024.
Eupraxia Pharmaceuticals Inc. (EPRX) financials
For fiscal 2025 (ended Dec 31, 2025), Eupraxia Pharmaceuticals Inc. reported $0 of revenue and -$38.58M of net income.
- Revenue, FY2025
- $0
- Net income, FY2025
- -$38.58M
- EPS, diluted, FY2025
- -$1.03
- Cash
- $80.56M
- Market cap
- $489.0M
FY2023FY2025
FY2022FY2025
EPRX revenue and earnings growth
EPRX net incomeFY2025-$38.58M
EPRX net income was -$38.58M for fiscal 2025 (ended Dec 31, 2025), compared with -$25.50M in fiscal 2024.
EPRX EPSFY2025-$1.03
EPRX diluted EPS was -$1.03 for fiscal 2025 (ended Dec 31, 2025), compared with -$0.76 in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | - |
| Research and development | $21.33M | $16.08M | $20.36M | $13.63M |
| Selling, general and admin | $17.10M | $10.92M | $7.48M | $3.99M |
| Interest expense | $0 | $603.6K | $1.17M | $982.9K |
| Pre-tax income | -$38.59M | -$25.74M | -$28.93M | -$18.99M |
| Income tax | $19.1K | $1.8K | $36.4K | $0 |
| Net income | -$38.58M | -$25.50M | -$28.22M | -$18.49M |
| EPS, basic | -$1.03 | -$0.76 | -$1.17 | -$0.96 |
| EPS, diluted | -$1.03 | -$0.76 | -$1.17 | -$0.96 |
| Diluted shares | 40.0M | 33.9M | 24.1M | 19.3M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Cash and equivalents | $80.56M | $33.10M | $19.34M | $18.26M |
| Receivables | $716.1K | $258.1K | $153.7K | - |
| Current assets | $85.10M | $34.44M | $19.80M | $18.59M |
| Total assets | $86.15M | $34.94M | $20.27M | $19.12M |
| Current liabilities | $5.63M | $3.10M | $19.37M | $3.06M |
| Total liabilities | $5.70M | $3.10M | $19.37M | $11.91M |
| Shareholders' equity | $82.04M | $33.40M | $892.3K | $7.21M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
|---|---|---|---|---|
| Operating cash flow | -$28.55M | -$29.99M | -$20.75M | -$14.40M |
| Investing cash flow | -$588.9K | -$75.2K | -$73.4K | $9.83M |
| Financing cash flow | $76.06M | $45.78M | $21.08M | $10.80M |
| Stock-based compensation | $8.76M | $3.22M | $1.41M | $1.43M |
Key ratios
Source: XBRL data Eupraxia Pharmaceuticals Inc. files with the SEC, latest filing dated Mar 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
EPRX FAQ
6 questionsWhat is EPRX revenue?
Eupraxia Pharmaceuticals Inc. (EPRX) reported $0 of revenue for fiscal 2025 (ended Dec 31, 2025).Is EPRX profitable?
No. Eupraxia Pharmaceuticals Inc. reported a net loss of $38.58M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does EPRX have?
Eupraxia Pharmaceuticals Inc. reported $80.56M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is EPRX earnings per share?
Diluted earnings per share were -$1.03 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did EPRX last report financial results?
The latest statements here come from Eupraxia Pharmaceuticals Inc.'s 40-F filed on Mar 13, 2026, covering the period ended Dec 31, 2025.Where does this EPRX financial data come from?
Quantisnow builds these statements from the structured XBRL data Eupraxia Pharmaceuticals Inc. files with the SEC. It is provided for information only and is not investment advice.